Evidence map›Paper›PMID 31659218›Full record

Trial reportScientific reports2019

Early renal dysfunction and fibroblast growth factor-23 in patients with small vessel disease-related stroke.

Simon Fandler-Höfler, Christian Enzinger, Markus Kneihsl, Daniela Pinter, Sebastian Eppinger, Barbara Obermayer-Pietsch, Anna Goritschan, Hildegard Hafner-Giessauf, Alexander R Rosenkranz, Franz Fazekas and 1 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. High Level of Physical Activity Reduces the Risk of Renal Progression in Hypertensive Patients.International journal of environmental research and public health · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Simon Fandler-HöflerDepartment of Neurology, Medical University of Graz, Graz, Austria.ORCID http://orcid.org/0000-0001-9043-0378
Christian EnzingerDepartment of Neurology, Medical University of Graz, Graz, Austria.
Markus KneihslDepartment of Neurology, Medical University of Graz, Graz, Austria.
Daniela PinterDepartment of Neurology, Medical University of Graz, Graz, Austria.ORCID http://orcid.org/0000-0003-3138-5225
Sebastian EppingerDepartment of Neurology, Medical University of Graz, Graz, Austria.
Barbara Obermayer-PietschDivision of Endocrinology and Diabetology, Endocrinology Lab Platform, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Anna GoritschanDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Hildegard Hafner-GiessaufDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Alexander R RosenkranzDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Franz FazekasDepartment of Neurology, Medical University of Graz, Graz, Austria.ORCID http://orcid.org/0000-0001-8155-7799
Thomas GattringerDepartment of Neurology, Medical University of Graz, Graz, Austria. thomas.gattringer@medunigraz.at.
Medical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interactions between cerebral small vessel disease (CSVD) and renal dysfunction (RD) have been reported, but previous studies were mostly retrospective and limited to measurements of estimated glomerular filtration rate (eGFR). In this prospective, longitudinal study of patients with CSVD-related recent small subcortical infarcts (RSSI), we aimed at a comprehensive exploration of markers of early RD and their association with microvascular brain damage. We investigated 101 stroke patients (mean age: 60.2 ± 10.7 years) with an MRI-confirmed RSSI who underwent follow-up brain MRI 15 months post-stroke. Besides serum creatinine and eGFR, we assessed urinary Albumin-Creatinine Ratio and fibroblast growth factor-23 (FGF-23). RD was classified according to recent Kidney Disease: Improving Global Outcomes criteria. We identified 24 patients with RD, only six patients revealed an eGFR <60 mL/min/1.73 m². RSSI patients with RD more often had severe white matter hyperintensities (WMH, 58% vs. 36%, p = 0.04). CSVD progression was not dependent on RD. However, patients in the highest FGF-23 quartile more frequently had new microangiopathic lesions on follow-up MRI (50% vs. 21%, p = 0.03). Early RD was found in a quarter of RSSI patients and associated with WMH severity, but not CSVD progression. High FGF-23 indicates an increased risk for ongoing microvascular brain damage, warranting further studies.

Indexed as

Cerebral Small Vessel DiseasesKidney DiseasesMagnetic Resonance ImagingStrokeAgedFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factors

Identifiers

PMID31659218
PMCPMC6817845
OpenAlexW2981737392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.